Endothelin in Nondiabetic Chronic Kidney Disease: Preclinical and Clinical Studies

Seminars in Nephrology

Volumn 35, Issue 2, 2015, Pages 176-187

  Culshaw, Geoff J ^a   MacIntyre, Iain M ^a   Dhaun, Neeraj ^a   Webb, David J ^a  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

Blood pressure; Chronic kidney disease; Endothelin; Endothelin receptor antagonist; Proteinuria

Indexed keywords

BOSENTAN; CYCLO(DEXTRO TRYPTOPHYL DEXTRO ASPARTYLPROLYL DEXTRO VALYLLEUCYL); ENALAPRIL; ENDOTHELIN; ENDOTHELIN 1; ENDOTHELIN 2; ENDOTHELIN 3; ENDOTHELIN A RECEPTOR; N (2,6 DIMETHYLPIPERIDINOCARBONYL) 4 METHYLLEUCYL DEXTRO (1 METHOXYCARBONYLTRYPTOPHANYL) DEXTRO NORLEUCINE; NIFEDIPINE; SITAXSENTAN; SPARSENTAN; TAK 044;

CHRONIC KIDNEY DISEASE; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG RESPONSE; FOCAL GLOMERULOSCLEROSIS; GLOMERULONEPHRITIS; HUMAN; KIDNEY FIBROSIS; KIDNEY POLYCYSTIC DISEASE; KIDNEY SURGERY; NONHUMAN; PATHOGENESIS; PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL (TOPIC); REGULATORY MECHANISM; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RENOVASCULAR HYPERTENSION; REVIEW; ANIMAL; BLOOD PRESSURE; CHRONIC KIDNEY FAILURE; METABOLISM; PATHOPHYSIOLOGY; PHYSIOLOGY;

ANIMALS; BLOOD PRESSURE; ENDOTHELINS; HUMANS; RENAL INSUFFICIENCY, CHRONIC;

EID: 84929044808     PISSN: 02709295     EISSN: 15584488     Source Type: Journal    
DOI: 10.1016/j.semnephrol.2015.03.002     Document Type: Review

References (121)

1. KDOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 2002, 39:S1-246.
2. Chronic kidney disease: early identification and management of chronic kidney disease in adults in primary and secondary care NICE. Clinical Guideline 182. 2014 2008, Available from: www.nice.org.uk/guidance/CG182 (Last accessed 03/13/2015).
3. Hallan S.I., Coresh J., Astor B.C., Asberg A., Powe N.R., Romundstad S., et al. International comparison of the relationship of chronic kidney disease prevalence and ESRD risk. J Am Soc Nephrol 2006, 17:2275-2284.
4. Sarnak M.J., Levey A.S., Schoolwerth A.C., Coresh J., Culleton B., Hamm L.L., et al. Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Circulation 2003, 108:2154-2169.
5. Levey A.S., Beto J.A., Coronado B.E., Eknoyan G., Foley R.N., Kasiske B.L., et al. Controlling the epidemic of cardiovascular disease in chronic renal disease: what do we know? What do we need to learn? Where do we go from here? National Kidney Foundation Task Force on Cardiovascular Disease. Am J Kidney Dis 1998, 32:853-906.
6. Dhaun N., Goddard J., Webb D.J. The endothelin system and its antagonism in chronic kidney disease. J Am Soc Nephrol 2006, 17:943-955.
7. Kirkby N.S., Hadoke P.W., Bagnall A.J., Webb D.J. The endothelin system as a therapeutic target in cardiovascular disease: great expectations or bleak house?. Br J Pharmacol 2008, 153:1105-1119.
8. Gilg J., Rao A., Fogarty D.U.K. Renal Registry 15th annual report: chapter 1 UK RRT incidence in 2011: national and centre-specific analyses. Nephron Clin Pract 2013, 123(Suppl 1):1-28.
9. Donadio J.V., Grande J.P. IgA nephropathy. N Engl J Med 2002, 347:738-748.
10. Yanagisawa M., Kurihara H., Kimura S., Tomobe Y., Kobayashi M., Mitsui Y., et al. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature 1988, 332:411-415.
11. Furchgott R.F., Zawadzki J.V. The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature 1980, 288:373-376.
12. Inoue A., Yanagisawa M., Kimura S., Kasuya Y., Miyauchi T., Goto K., et al. The human endothelin family: three structurally and pharmacologically distinct isopeptides predicted by three separate genes. Proc Natl Acad Sci U S A 1989, 86:2863-2867.
13. Imig J.D., Pham B.T., LeBlanc E.A., Reddy K.M., Falck J.R., Inscho E.W. Cytochrome P450 and cyclooxygenase metabolites contribute to the endothelin-1 afferent arteriolar vasoconstrictor and calcium responses. Hypertension 2000, 35:307-312.
14. Inscho E.W., Imig J.D., Cook A.K., Pollock D.M. ETA and ETB receptors differentially modulate afferent and efferent arteriolar responses to endothelin. Br J Pharmacol 2005, 146:1019-1026.
15. D'Orleans-Juste P., Plante M., Honore J.C., Carrier E., Labonte J. Synthesis and degradation of endothelin-1. Can J Physiol Pharmacol 2003, 81:503-510.
16. Haynes W.G., Webb D.J. Contribution of endogenous generation of endothelin-1 to basal vascular tone. Lancet 1994, 344:852-854.
17. Ozaka T., Doi Y., Kayashima K., Fujimoto S. Weibel-Palade bodies as a storage site of calcitonin gene-related peptide and endothelin-1 in blood vessels of the rat carotid body. Anat Rec 1997, 247:388-394.
18. Gasic S., Wagner O.F., Vierhapper H., Nowotny P., Waldhausl W. Regional hemodynamic effects and clearance of endothelin-1 in humans: renal and peripheral tissues may contribute to the overall disposal of the peptide. J Cardiovasc Pharmacol 1992, 19:176-180.
19. Dupuis J., Stewart D.J., Cernacek P., Gosselin G. Human pulmonary circulation is an important site for both clearance and production of endothelin-1. Circulation 1996, 94:1578-1584.
20. Abassi Z.A., Tate J.E., Golomb E., Keiser H.R. Role of neutral endopeptidase in the metabolism of endothelin. Hypertension 1992, 20:89-95.
21. Bohm F., Pernow J., Lindstrom J., Ahlborg G. ETA receptors mediate vasoconstriction, whereas ETB receptors clear endothelin-1 in the splanchnic and renal circulation of healthy men. Clin Sci (Lond) 2003, 104:143-151.
22. Parvanova A., van der Meer I.M., Iliev I., Perna A., Gaspari F., Trevisan R., et al. Effect on blood pressure of combined inhibition of endothelin-converting enzyme and neutral endopeptidase with daglutril in patients with type 2 diabetes who have albuminuria: a randomised, crossover, double-blind, placebo-controlled trial. Lancet Diabetes Endocrinol 2013, 1:19-27.
23. Kohan D.E., Rossi N.F., Inscho E.W., Pollock D.M. Regulation of blood pressure and salt homeostasis by endothelin. Physiol Rev 2011, 91:1-77.
24. Bidani A.K., Griffin K.A. Pathophysiology of hypertensive renal damage: implications for therapy. Hypertension 2004, 44:595-601.
25. Shindo T., Kurihara H., Maemura K., Kurihara Y., Ueda O., Suzuki H., et al. Renal damage and salt-dependent hypertension in aged transgenic mice overexpressing endothelin-1. J Mol Med (Berl) 2002, 80:105-116.
26. Hocher B., Thone-Reineke C., Rohmeiss P., Schmager F., Slowinski T., Burst V., et al. Endothelin-1 transgenic mice develop glomerulosclerosis, interstitial fibrosis, and renal cysts but not hypertension. J Clin Invest 1997, 99:1380-1389.
27. Kitamura K., Tanaka T., Kato J., Ogawa T., Eto T., Tanaka K. Immunoreactive endothelin in rat kidney inner medulla: marked decrease in spontaneously hypertensive rats. Biochem Biophys Res Commun 1989, 162:38-44.
28. Kuc R., Davenport A.P. Comparison of endothelin-A and endothelin-B receptor distribution visualized by radioligand binding versus immunocytochemical localization using subtype selective antisera. J Cardiovasc Pharmacol 2004, 44(Suppl 1):S224-S226.
29. Pupilli C., Brunori M., Misciglia N., Selli C., Ianni L., Yanagisawa M., et al. Presence and distribution of endothelin-1 gene expression in human kidney. Am J Physiol 1994, 267:F679-F687.
30. Ahn D., Ge Y., Stricklett P.K., Gill P., Taylor D., Hughes A.K., et al. Collecting duct-specific knockout of endothelin-1 causes hypertension and sodium retention. J Clin Invest 2004, 114:504-511.
31. Ge Y., Bagnall A., Stricklett P.K., Strait K., Webb D.J., Kotelevtsev Y., et al. Collecting duct-specific knockout of the endothelin B receptor causes hypertension and sodium retention. Am J Physiol Renal Physiol 2006, 291:F1274-F1280.
32. Lyon-Roberts B., Strait K.A., van Peursem E., Kittikulsuth W., Pollock J.S., Pollock D.M., et al. Flow regulation of collecting duct endothelin-1 production. Am J Physiol Renal Physiol 2011, 300:F650-F656.
33. Pandit M.M., Strait K.A., Matsuda T., Kohan D.E. Na delivery and ENaC mediate flow regulation of collecting duct endothelin-1 production. Am J Physiol Renal Physiol 2012, 302:F1325-F1330.
34. Schneider M.P., Ge Y., Pollock D.M., Pollock J.S., Kohan D.E. Collecting duct-derived endothelin regulates arterial pressure and Na excretion via nitric oxide. Hypertension 2008, 51:1605-1610.
35. Kohan D.E., Padilla E., Hughes A.K. Endothelin B receptor mediates ET-1 effects on cAMP and PGE2 accumulation in rat IMCD. Am J Physiol 1993, 265:F670-F676.
36. Ge Y., Stricklett P.K., Hughes A.K., Yanagisawa M., Kohan D.E. Collecting duct-specific knockout of the endothelin A receptor alters renal vasopressin responsiveness, but not sodium excretion or blood pressure. Am J Physiol Renal Physiol 2005, 289:F692-F698.
37. Nakano D., Pollock D.M. Contribution of endothelin A receptors in endothelin 1-dependent natriuresis in female rats. Hypertension 2009, 53:324-330.
38. Barton M., Kohan D.E. Endothelin antagonists in clinical trials: lessons learned. Contrib Nephrol 2011, 172:255-260.
39. Fizazi K.S., Higano C.S., Nelson J.B., Gleave M., Miller K., Morris T., et al. Phase III, randomized, placebo-controlled study of docetaxel in combination with zibotentan in patients with metastatic castration-resistant prostate cancer. J Clin Oncol 2013, 31:1740-1747.
40. Schneider M.P., Inscho E.W., Pollock D.M. Attenuated vasoconstrictor responses to endothelin in afferent arterioles during a high-salt diet. Am J Physiol Renal Physiol 2007, 292:F1208-F1214.
41. Fligny C., Barton M., Tharaux P.L. Endothelin and podocyte injury in chronic kidney disease. Contrib Nephrol 2011, 172:120-138.
42. Grahammer F., Schell C., Huber T.B. The podocyte slit diaphragm--from a thin grey line to a complex signalling hub. Nat Rev Nephrol 2013, 9:587-598.
43. Morigi M., Buelli S., Zanchi C., Longaretti L., Macconi D., Benigni A., et al. Shigatoxin-induced endothelin-1 expression in cultured podocytes autocrinally mediates actin remodeling. Am J Pathol 2006, 169:1965-1975.
44. Morigi M., Buelli S., Angioletti S., Zanchi C., Longaretti L., Zoja C., et al. In response to protein load podocytes reorganize cytoskeleton and modulate endothelin-1 gene: implication for permselective dysfunction of chronic nephropathies. Am J Pathol 2005, 166:1309-1320.
45. Ortmann J., Amann K., Brandes R.P., Kretzler M., Munter K., Parekh N., et al. Role of podocytes for reversal of glomerulosclerosis and proteinuria in the aging kidney after endothelin inhibition. Hypertension 2004, 44:974-981.
46. Remuzzi G., Bertani T. Pathophysiology of progressive nephropathies. N Engl J Med 1998, 339:1448-1456.
47. Hillege H.L., Fidler V., Diercks G.F., van Gilst W.H., de Zeeuw D., van Veldhuisen D.J., et al. Urinary albumin excretion predicts cardiovascular and noncardiovascular mortality in general population. Circulation 2002, 106:1777-1782.
48. Collino F., Bussolati B., Gerbaudo E., Marozio L., Pelissetto S., Benedetto C., et al. Preeclamptic sera induce nephrin shedding from podocytes through endothelin-1 release by endothelial glomerular cells. Am J Physiol Renal Physiol 2008, 294:F1185-F1194.
49. Barton M., Shaw S., d'Uscio L.V., Moreau P., Luscher T.F. Angiotensin II increases vascular and renal endothelin-1 and functional endothelin converting enzyme activity in vivo: role of ETA receptors for endothelin regulation. Biochem Biophys Res Commun 1997, 238:861-865.
50. Matsumura Y., Nakase K., Ikegawa R., Hayashi K., Ohyama T., Morimoto S. The endothelium-derived vasoconstrictor peptide endothelin inhibits renin release in vitro. Life Sci 1989, 44:149-157.
51. Otsuka A., Mikami H., Katahira K., Tsunetoshi T., Minamitani K., Ogihara T. Changes in plasma renin activity and aldosterone concentration in response to endothelin injection in dogs. Acta Endocrinol (Copenh) 1989, 121:361-364.
52. Kawaguchi H., Sawa H., Yasuda H. Endothelin stimulates angiotensin I to angiotensin II conversion in cultured pulmonary artery endothelial cells. J Mol Cell Cardiol 1990, 22:839-842.
53. Schiffrin E.L. The angiotensin-endothelin relationship: does it play a role in cardiovascular and renal pathophysiology?. J Hypertens 2003, 21:2245-2247.
54. Cui P., Tani K., Kitamura H., Okumura Y., Yano M., Inui D., et al. A novel bioactive 31-amino acid endothelin-1 is a potent chemotactic peptide for human neutrophils and monocytes. J Leukoc Biol 2001, 70:306-312.
55. Achmad T.H., Rao G.S. Chemotaxis of human blood monocytes toward endothelin-1 and the influence of calcium channel blockers. Biochem Biophys Res Commun 1992, 189:994-1000.
56. Javeshghani D., Barhoumi T., Idris-Khodja N., Paradis P., Schiffrin E.L. Reduced macrophage-dependent inflammation improves endothelin-1-induced vascular injury. Hypertension 2013, 62:112-117.
57. Saleh M.A., Pollock J.S., Pollock D.M. Distinct actions of endothelin A-selective versus combined endothelin A/B receptor antagonists in early diabetic kidney disease. J Pharmacol Exp Ther 2011, 338:263-270.
58. Bacon C.R., Cary N.R., Davenport A.P. Endothelin peptide and receptors in human atherosclerotic coronary artery and aorta. Circ Res 1996, 79:794-801.
59. Ehrenreich H., Anderson R.W., Fox C.H., Rieckmann P., Hoffman G.S., Travis W.D., et al. Endothelins, peptides with potent vasoactive properties, are produced by human macrophages. J Exp Med 1990, 172:1741-1748.
60. Kluth D.C. Pro-resolution properties of macrophages in renal injury. Kidney Int 2007, 72:234-236.
61. Wang Y., Wang Y.P., Zheng G., Lee V.W., Ouyang L., Chang D.H., et al. Ex vivo programmed macrophages ameliorate experimental chronic inflammatory renal disease. Kidney Int 2007, 72:290-299.
62. Helset E., Sildnes T., Seljelid R., Konopski Z.S. Endothelin-1 stimulates human monocytes in vitro to release TNF-alpha, IL-1beta and IL-6. Mediators Inflamm 1993, 2:417-422.
63. Ruetten H., Thiemermann C. Endothelin-1 stimulates the biosynthesis of tumour necrosis factor in macrophages: ET-receptors, signal transduction and inhibition by dexamethasone. J Physiol Pharmacol 1997, 48:675-688.
64. Foschi M., Sorokin A., Pratt P., McGinty A., La Villa G., Franchi F., et al. PreproEndothelin-1 expression in human mesangial cells: evidence for a p38 mitogen-activated protein kinase/protein kinases-C-dependent mechanism. J Am Soc Nephrol 2001, 12:1137-1150.
65. Chatziantoniou C., Dussaule J.C. Insights into the mechanisms of renal fibrosis: is it possible to achieve regression?. Am J Physiol Renal Physiol 2005, 289:F227-F234.
66. Zoja C., Morigi M., Figliuzzi M., Bruzzi I., Oldroyd S., Benigni A., et al. Proximal tubular cell synthesis and secretion of endothelin-1 on challenge with albumin and other proteins. Am J Kidney Dis 1995, 26:934-941.
67. Ong A.C., Jowett T.P., Firth J.D., Burton S., Kitamura M., Fine L.G. Human tubular-derived endothelin in the paracrine regulation of renal interstitial fibroblast function. Exp Nephrol 1994, 2:134.
68. Stockand J.D., Sansom S.C. Glomerular mesangial cells: electrophysiology and regulation of contraction. Physiol Rev 1998, 78:723-744.
69. Gomez-Garre D., Ruiz-Ortega M., Ortego M., Largo R., Lopez-Armada M.J., Plaza J.J., et al. Effects and interactions of endothelin-1 and angiotensin II on matrix protein expression and synthesis and mesangial cell growth. Hypertension 1996, 27:885-892.
70. Simonson M.S., Ismail-Beigi F. Endothelin-1 increases collagen accumulation in renal mesangial cells by stimulating a chemokine and cytokine autocrine signaling loop. J Biol Chem 2011, 286:11003-11008.
71. Guyton A.C. Renal function curve--a key to understanding the pathogenesis of hypertension. Hypertension 1987, 10:1-6.
72. Crawford C., Kennedy-Lydon T., Sprott C., Desai T., Sawbridge L., Munday J., et al. An intact kidney slice model to investigate vasa recta properties and function in situ. Nephron Physiol 2012, 120:17-31.
73. Silldorff E.P., Yang S., Pallone T.L. Prostaglandin E2 abrogates endothelin-induced vasoconstriction in renal outer medullary descending vasa recta of the rat. J Clin Invest 1995, 95:2734-2740.
74. O'Connor P.M., Cowley A.W. Medullary thick ascending limb buffer vasoconstriction of renal outer-medullary vasa recta in salt-resistant but not salt-sensitive rats. Hypertension 2012, 60:965-972.
75. Ahmeda A.F., Johns E.J. The regulation of blood perfusion in the renal cortex and medulla by reactive oxygen species and nitric oxide in the anaesthetised rat. Acta Physiol (Oxf) 2012, 204:443-450.
76. Roman R.J., Cowley A.W., Garcia-Estan J., Lombard J.H. Pressure-diuresis in volume-expanded rats. Cortical and medullary hemodynamics. Hypertension 1988, 12:168-176.
77. Lim S.S., Vos T., Flaxman A.D., Danaei G., Shibuya K., Adair-Rohani H., et al. A comparative risk assessment of burden of disease and injury attributable to 67 risk factors and risk factor clusters in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012, 380:2224-2260.
78. Collins A.J., Foley R.N., Chavers B., Gilbertson D., Herzog C., Ishani A., et al. US Renal Data System 2013 Annual Data Report. Am J Kidney Dis 2014, 63:A7.
79. Freedman B.I., Sedor J.R. Hypertension-associated kidney disease: perhaps no more. J Am Soc Nephrol 2008, 19:2047-2051.
80. Hocher B., Rohmeiss P., Zart R., Diekmann F., Vogt V., Metz D., et al. Significance of endothelin receptor subtypes in the kidneys of spontaneously hypertensive rats: renal and hemodynamic effects of endothelin receptor antagonists. J Cardiovasc Pharmacol 1995, 26(Suppl 3):S470-S472.
81. Kittikulsuth W., Pollock J.S., Pollock D.M. Sex differences in renal medullary endothelin receptor function in angiotensin II hypertensive rats. Hypertension 2011, 58:212-218.
82. Kassab S., Miller M.T., Novak J., Reckelhoff J., Clower B., Granger J.P. Endothelin-A receptor antagonism attenuates the hypertension and renal injury in Dahl salt-sensitive rats. Hypertension 1998, 31:397-402.
83. Nagase M., Shibata S., Yoshida S., Nagase T., Gotoda T., Fujita T. Podocyte injury underlies the glomerulopathy of Dahl salt-hypertensive rats and is reversed by aldosterone blocker. Hypertension 2006, 47:1084-1093.
84. Saleh M.A., Boesen E.I., Pollock J.S., Savin V.J., Pollock D.M. Endothelin-1 increases glomerular permeability and inflammation independent of blood pressure in the rat. Hypertension 2010, 56:942-949.
85. Trenkner J., Priem F., Bauer C., Neumayer H.H., Raschak M., Hocher B. Endothelin receptor A blockade reduces proteinuria and vascular hypertrophy in spontaneously hypertensive rats on high-salt diet in a blood-pressure-independent manner. Clin Sci (Lond) 2002, 103(Suppl 48):385S-388SS.
86. Tostes R.C., Touyz R.M., He G., Ammarguellat F., Schiffrin E.L. Endothelin A receptor blockade decreases expression of growth factors and collagen and improves matrix metalloproteinase-2 activity in kidneys from stroke-prone spontaneously hypertensive rats. J Cardiovasc Pharmacol 2002, 39:892-900.
87. Opocensky M., Kramer H.J., Backer A., Vernerova Z., Eis V., Cervenka L., et al. Late-onset endothelin-A receptor blockade reduces podocyte injury in homozygous Ren-2 rats despite severe hypertension. Hypertension 2006, 48:965-971.
88. Lurbe E., Redon J., Kesani A., Pascual J.M., Tacons J., Alvarez V., et al. Increase in nocturnal blood pressure and progression to microalbuminuria in type 1 diabetes. N Engl J Med 2002, 347:797-805.
89. Fukuda M., Munemura M., Usami T., Nakao N., Takeuchi O., Kamiya Y., et al. Nocturnal blood pressure is elevated with natriuresis and proteinuria as renal function deteriorates in nephropathy. Kidney Int 2004, 65:621-625.
90. Dhaun N., Moorhouse R., MacIntyre I.M., Melville V., Oosthuyzen W., Kimmitt R.A., et al. Diurnal variation in blood pressure and arterial stiffness in chronic kidney disease: the role of endothelin-1. Hypertension 2014, 64:296-304.
91. Diekmann F., Zart R., Thone-Reineke C., Bauer C., Neumayer H.H., Hocher B. Regulation of the renal endothelin system in the two-kidney, one clip renal hypertensive rat. J Cardiovasc Pharmacol 2000, 36:S191-S194.
92. Hocher B., George I., Diekmann F., Zart R., Rebstock J., Schwarz A., et al. ETA receptor blockade induces fibrosis of the clipped kidney in two-kidney-one-clip renovascular hypertensive rats. J Hypertens 2000, 18:1807-1814.
93. Benigni A., Perico N., Gaspari F., Zoja C., Bellizzi L., Gabanelli M., et al. Increased renal endothelin production in rats with reduced renal mass. Am J Physiol 1991, 260:F331-F339.
94. Orisio S., Benigni A., Bruzzi I., Corna D., Perico N., Zoja C., et al. Renal endothelin gene expression is increased in remnant kidney and correlates with disease progression. Kidney Int 1993, 43:354-358.
95. Goddard J., Johnston N.R., Cumming A.D., Webb D.J. Fractional urinary excretion of endothelin-1 is reduced by acute ETB receptor blockade. Am J Physiol Renal Physiol 2007, 293:F1433-F1438.
96. Benigni A., Zoja C., Corna D., Orisio S., Longaretti L., Bertani T., et al. A specific endothelin subtype A receptor antagonist protects against injury in renal disease progression. Kidney Int 1993, 44:440-444.
97. Pollock D.M., Polakowski J.S. ETA receptor blockade prevents hypertension associated with exogenous endothelin-1 but not renal mass reduction in the rat. J Am Soc Nephrol 1997, 8:1054-1060.
98. Coresh J., Selvin E., Stevens L.A., Manzi J., Kusek J.W., Eggers P., et al. Prevalence of chronic kidney disease in the United States. JAMA 2007, 298:2038-2047.
99. Lenoir O., Milon M., Virsolvy A., Henique C., Schmitt A., Masse J.M., et al. Direct action of endothelin-1 on podocytes promotes diabetic glomerulosclerosis. J Am Soc Nephrol 2014, 25:1050-1062.
100. Gomez-Garre D., Largo R., Liu X.H., Gutierrez S., Lopez-Armada M.J., Palacios I., et al. An orally active ETA/ETB receptor antagonist ameliorates proteinuria and glomerular lesions in rats with proliferative nephritis. Kidney Int 1996, 50:962-972.
101. Benigni A., Corna D., Maffi R., Benedetti G., Zoja C., Remuzzi G. Renoprotective effect of contemporary blocking of angiotensin II and endothelin-1 in rats with membranous nephropathy. Kidney Int 1998, 54:353-359.
102. Barua M., Cil O., Paterson A.D., Wang K., He N., Dicks E., et al. Family history of renal disease severity predicts the mutated gene in ADPKD. J Am Soc Nephrol 2009, 20:1833-1838.
103. Peters D.J., Breuning M.H. Autosomal dominant polycystic kidney disease: modification of disease progression. Lancet 2001, 358:1439-1444.
104. Hocher B., Zart R., Braun N., Schwarz A., van der Woude F., Rohmeiss P., et al. The endothelin system in polycystic kidneys of Han:SPRD rats. J Cardiovasc Pharmacol 1998, 31(Suppl 1):S342-S344.
105. Nakamura T., Ebihara I., Fukui M., Osada S., Tomino Y., Masaki T., et al. Increased endothelin and endothelin receptor mRNA expression in polycystic kidneys of cpk mice. J Am Soc Nephrol 1993, 4:1064-1072.
106. Schieren G., Rumberger B., Klein M., Kreutz C., Wilpert J., Geyer M., et al. Gene profiling of polycystic kidneys. Nephrol Dial Transplant 2006, 21:1816-1824.
107. Hocher B., Kalk P., Slowinski T., Godes M., Mach A., Herzfeld S., et al. ETA receptor blockade induces tubular cell proliferation and cyst growth in rats with polycystic kidney disease. J Am Soc Nephrol 2003, 14:367-376.
108. Chang M.Y., Parker E., El Nahas M., Haylor J.L., Ong A.C. Endothelin B receptor blockade accelerates disease progression in a murine model of autosomal dominant polycystic kidney disease. J Am Soc Nephrol 2007, 18:560-569.
109. Peralta C.A., Hicks L.S., Chertow G.M., Ayanian J.Z., Vittinghoff E., Lin F., et al. Control of hypertension in adults with chronic kidney disease in the United States. Hypertension 2005, 45:1119-1124.
110. Ruggenenti P., Perticucci E., Cravedi P., Gambara V., Costantini M., Sharma S.K., et al. Role of remission clinics in the longitudinal treatment of CKD. J Am Soc Nephrol 2008, 19:1213-1224.
111. Goddard J., Johnston N.R., Hand M.F., Cumming A.D., Rabelink T.J., Rankin A.J., et al. Endothelin-A receptor antagonism reduces blood pressure and increases renal blood flow in hypertensive patients with chronic renal failure: a comparison of selective and combined endothelin receptor blockade. Circulation 2004, 109:1186-1193.
112. Dhaun N., Macintyre I.M., Melville V., Lilitkarntakul P., Johnston N.R., Goddard J., et al. Blood pressure-independent reduction in proteinuria and arterial stiffness after acute endothelin-a receptor antagonism in chronic kidney disease. Hypertension 2009, 54:113-119.
113. Dhaun N., Macintyre I.M., Melville V., Lilitkarntakul P., Johnston N.R., Goddard J., et al. Effects of endothelin receptor antagonism relate to the degree of renin-angiotensin system blockade in chronic proteinuric kidney disease. Hypertension 2009, 54:e19-e20.
114. Goddard J., Eckhart C., Johnston N.R., Cumming A.D., Rankin A.J., Webb D.J. Endothelin A receptor antagonism and angiotensin-converting enzyme inhibition are synergistic via an endothelin B receptor-mediated and nitric oxide-dependent mechanism. J Am Soc Nephrol 2004, 15:2601-2610.
115. Vlachopoulos C., Aznaouridis K., Stefanadis C. Prediction of cardiovascular events and all-cause mortality with arterial stiffness: a systematic review and meta-analysis. J Am Coll Cardiol 2010, 55:1318-1327.
116. Dhaun N., Melville V., Blackwell S., Talwar D.K., Johnston N.R., Goddard J., et al. Endothelin-A receptor antagonism modifies cardiovascular risk factors in CKD. J Am Soc Nephrol 2013, 24:31-36.
117. MacIntyre I.M., Dhaun N., Lilitkarntakul P., Melville V., Goddard J., Webb D.J. Greater functional ETB receptor antagonism with bosentan than sitaxsentan in healthy men. Hypertension 2010, 55:1406-1411.
118. Galie N., Hoeper M.M., Simon J., Gibbs R., Simonneau G. Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), et al. Liver toxicity of sitaxentan in pulmonary arterial hypertension. Eur Heart J 2011, 32:386-387.
119. Stevens L.A., Greene T., Levey A.S. Surrogate end points for clinical trials of kidney disease progression. Clin J Am Soc Nephrol 2006, 1:874-884.
120. Levey A.S., Cattran D., Friedman A., Miller W.G., Sedor J., Tuttle K., et al. Proteinuria as a surrogate outcome in CKD: report of a scientific workshop sponsored by the National Kidney Foundation and the US Food and Drug Administration. Am J Kidney Dis 2009, 54:205-226.
121. Dhaun N., Ferro C.J., Davenport A.P. Haemodynamic and renal effects of endothelin receptor antagonism in patients with chronic kidney disease. Nephrol Dial Transplant 2007, 22:2328-2334.